Evidence map›Paper›PMID 31271790›Full record

ArticleJournal of virological methods2019

Analytical evaluation of the microarray-based FluChip-8G Influenza A+B Assay.

Amber W Taylor, Erica D Dawson, Rebecca H Blair, James E Johnson, Amelia H Slinskey, Andrew W Smolak, Evan Toth, Kyle Liikanen, Robert S Stoughton, Catherine Smith and 2 more

Abstract readEvaluation StudyMulticenter Study
In one paragraph

Article in Journal of virological methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinical validation of the FluChip-8G Influenza A+B Assay for influenza type and subtype identification.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amber W TaylorInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Erica D DawsonInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA. Electronic address: dawson@indevr.com.
Rebecca H BlairInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
James E JohnsonInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Amelia H SlinskeyInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Andrew W SmolakInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Evan TothInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Kyle LiikanenInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Robert S StoughtonInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.
Catherine SmithInfluenza Division, The Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30333, USA.
Sarah TalbotInfluenza Division, The Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30333, USA.
Kathy L RowlenInDevR, Inc., 2100 Central Avenue, Suite 106, Boulder, CO, 80301, USA.

Funding

SIMULTANEOUS SCREENING FOR A/H3N2, A/H1N1, A/H5N1 AND B INFLUENZA VIRUSESR44AI077112 · NIAID · INDEVR, INC. · PI DAWSON, ERICA D · 2011 to 2013
$2.9M
SIMULTANEOUS SCREENING FOR A/H3N2, A/H1N1, A/H5N1 AND B INFLUENZA VIRUSESR43AI077112 · NIAID · INDEVR, INC. · PI DAWSON, ERICA D · 2008 to 2009
$597k
NIAID NIH HHS R43 AI077112NIAID NIH HHS R44 AI077112
6 · The paper itself

Abstract

backgroundInfluenza causes a significant annual disease burden, with characterization of the infecting virus important in clinical and public health settings. Rapid immunoassays are fast but insensitive, whereas real-time RT-PCR is sensitive but susceptible to genetic mutations and often requires multiple serial assays. The FluChip-8G Influenza A+B Assay provides type and subtype/lineage identification of influenza A and B, including non-seasonal A viruses, in a single microarray-based assay with same day turnaround time.

objectiveTo evaluate key analytical performance characteristics of the FluChip-8G Influenza A+B Assay. STUDY

designAnalytical sensitivity, cross-reactivity, and multi-site reproducibility were evaluated.

resultsThe limit of detection (LOD) for the FluChip-8G influenza A+B Assay ranged from 5.8 × 10

conclusionThe FluChip-8G Influenza A+B Assay is an effective new method for detecting and identifying both seasonal and non-seasonal influenza viruses, as revealed by good sensitivity and robust reactivity to 52 unique strains of influenza virus. In addition, the lack of cross-reactivity to non-influenza pathogens and high lab-to-lab reproducibility highlight the analytical performance of the assay as an alternative to real-time RT-PCR and sequencing-based assays. Clinical validation of the technology in a multi-site clinical study is the subject of a separate investigation.

Indexed as

Cross ReactionsGenome, ViralHumansInfluenza A virusInfluenza B virusInfluenza, HumanLimit of DetectionMicroarray AnalysisNoseReproducibility of ResultsSensitivity and SpecificityFluChip-8GInfluenza subtypingMicroarrayMultiplex RT-PCR

Identifiers

PMID31271790
PMCPMC6779046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.